Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma 6Urogenital Neoplasms 5Prostatic Neoplasms 5Prostatic Diseases 5Neoplasms by Site 5Neoplasms 5Male Urogenital Diseases 5Genital Neoplasms, Male 5Genital Diseases, Male 4Transitional Cell Cancer of Renal Pelvis and Ureter 1Lung Neoplasms 1Localized Prostate Cancer 1Genital Diseases 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 82Cisplatin 52Oxaliplatin 36lenvatinib 24durvalumab 22Capecitabine 22Fluorouracil 20Leucovorin 15tislelizumab 11pembrolizumab 10apatinib 10Radiotherapy 10Albumin-Bound Paclitaxel 10Radiofrequency Ablation 9Magnetic Resonance Spectroscopy 9Irinotecan 9Floxuridine 9Liver Transplantation 8Drug Therapy 8Cholangiopancreatography, Endoscopic Retrograde 8130-nm albumin-bound paclitaxel 8Taxes 7Platinum 7Photochemotherapy 7Panitumumab 7Biopsy 71,2-diaminocyclohexaneplatinum II citrate 7tremelimumab 6pemigatinib 6camrelizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cholangiocarcinoma × padeliporfin × Clear all
NCT00975039 2016-04-18

Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Steba Biotech S.A.

Phase 2 Terminated
8 enrolled
Gastrointestinal

Carcinoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡